Doctor’s Guide -- CHICAGO -- October 26, 2010 -- An analysis of data from previously published studies indicates that use of clopidogrel for patients who have common genetic variants of a certain gene and are undergoing percutaneous coronary intervention (PCI) have an associated increased risk for major adverse cardiovascular events, particularly development of stent thrombosis, according to a study published in the October 27 issue of JAMA.
